BridgeBio Oncology Therapeutics, Inc.
BBOT · Pharmaceutical Preparations · 80.1M shares · EDGAR filings ↗
Grade
D46Clinical/early-stage biotech — oncology clinical, heavy burn ($115M), very cash-rich.
Strengths
- Liquidity — current ratio 12.3 (85th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Cash burnNegative free cash flow (-114.5M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Strong balance sheetStrong balance sheet — $426M cash & investments, ~15 quarters of runway
- Notable holderHeld by 5 notable fund(s): CITADEL ADVISORS LLC, FMR LLC, STATE STREET CORP +2 more (as of 2026-03-31)
Key metrics
Return on equity
-32.6%
Return on assets
-29.9%
Current ratio
12.3×
Free cash flow
-$114M
Tangible book value
$411M
Cash & investments
$426M
Cash runway
15q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-01 | Ben Yong | Tax withheld | 1.0K | $9.03 |
| 2026-04-01 | Beltran Pedro | Tax withheld | 1.0K | $9.03 |
| 2026-04-01 | Mehra Uneek | Tax withheld | 524 | $9.03 |
| 2026-03-10 | Mehra Uneek | Grant | 23K | — |
| 2026-03-10 | Beltran Pedro | Grant | 47K | — |
| 2026-03-10 | Ben Yong | Grant | 47K | — |
| 2025-10-10 | BridgeBio Pharma LLC | Other | 785K | — |
| 2025-08-11 | Chen Bihua | Disposition | 153K | — |
| 2025-08-11 | Chen Bihua | Grant | 760K | $10.72 |
| 2025-08-11 | Chen Bihua | Grant | 639K | $10.72 |
| 2025-08-11 | Chen Bihua | Grant | 5.6M | $10.72 |
| 2025-08-11 | Chen Bihua | Grant | 1.9M | — |
| 2025-08-11 | Chen Bihua | Grant | 1.8M | — |
| 2025-08-11 | Chen Bihua | Grant | 285K | — |
| 2025-08-11 | Holman Albert A III | Option exercise | 30K | — |
| 2025-08-11 | McKenna Mark C. | Option exercise | 30K | — |
| 2025-08-11 | Schmid John P. | Option exercise | 30K | — |
| 2025-08-11 | Chen Bihua | Option exercise | 4.2M | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06343402 ↗ | Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer | PHASE1 | Recruiting | 2031-04-01 |
| NCT06625775 ↗ | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors Solid Tumor, Adult, Metastatic Breast Cancer | PHASE1 | Recruiting | 2028-11-01 |
| NCT06917079 ↗ | BBO-11818 in Adult Subjects With KRAS Mutant Cancer Non-Small Cell Lung Cancer, NSCLC | PHASE1 | Recruiting | 2027-08-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-22 | Exec/director changeShareholder vote | filing ↗ |
| 2026-05-12 | ResultsExhibits | filing ↗ |
| 2026-04-29 | Exec/director change | filing ↗ |
| 2026-04-23 | Exec/director changeReg FDExhibits | filing ↗ |
| 2026-03-26 | Exec/director change | filing ↗ |
| 2026-03-05 | ResultsExhibits | filing ↗ |
| 2026-01-07 | OtherExhibits | filing ↗ |
| 2025-11-12 | ResultsExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-22 | 2026-06-16 | 0001193125-26-277513 ↗ |
| 8-K | 2026-05-12 | 2026-05-12 | 0001193125-26-219801 ↗ |
| 10-Q | 2026-05-12 | 2026-03-31 | 0001193125-26-219829 ↗ |
| 8-K | 2026-04-29 | 2026-04-27 | 0001193125-26-191512 ↗ |
| 8-K | 2026-04-23 | 2026-04-20 | 0001193125-26-170888 ↗ |
| 8-K | 2026-03-26 | 2026-03-24 | 0001193125-26-126493 ↗ |
| 10-K | 2026-03-05 | 2025-12-31 | 0001193125-26-094112 ↗ |
| 8-K | 2026-03-05 | 2026-03-05 | 0001193125-26-093997 ↗ |
| 8-K | 2026-01-07 | 2026-01-07 | 0001193125-26-005425 ↗ |
| 10-Q | 2025-11-12 | 2025-09-30 | 0001193125-25-277834 ↗ |
| 8-K | 2025-11-12 | 2025-11-12 | 0001193125-25-277601 ↗ |
| 8-K | 2025-08-13 | 2025-08-11 | 0001213900-25-075190 ↗ |